DNM1L and cancer: The main focus of some anti-cancer drugs is to inhibit mitochondrial division by preventing the recruitment of Drp1, inhibiting ERK1/2 phosphorylation, and dephosphorylating Drp1 at Ser616 (Fig. 2A).